Lonza Joins DSM as Manufacturer of Biopharma Drug for Agennix
09:55 AM | April 12, 2012 | Alex Scott
Lonza has agreed to supply Agennix (Heidelberg, Germany), a biotech firm, with commercial quantities of talactoferrin, Agennix’s trial drug for the treatment of non-small cell lung cancer (NSCLC). As...
This information is only available to subscribers.
chemweek.com is the one stop platform for chemical news, data and analysis across all industry sectors and geographies.